Investors with Losses Over $100K Can Join Capricor Lawsuit Against Securities Fraud

Capricor Therapeutics Investors Take Action

In an important move for investors, the Rosen Law Firm has issued a reminder for those who bought securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024, and July 10, 2025. If you experienced losses exceeding $100,000 during this time frame, you could be eligible to take part in a class action lawsuit regarding securities fraud, with the lead plaintiff deadline set for September 15, 2025.

Why You Should Act Now

Investors holding shares during the specified period are encouraged to join the legal action without incurring upfront costs. The Rosen Law Firm operates on a contingency fee basis, meaning you won’t have to pay any fees unless the lawsuit is successful. This provides a unique opportunity for those affected to recover potential losses.

To participate in this class action lawsuit, interested investors can visit Rosen Law Firm's website or contact Phillips Kim, Esq. via email at [email protected] or phone at 866-767-3653 for further information.

Background on Capricor and the Lawsuit

The heart of the legal action revolves around claims that Capricor provided misleading information about its lead cell therapy drug, deramiocel, which is intended to treat cardiomyopathy related to Duchenne muscular dystrophy (DMD). The lawsuit posits that Capricor's representations to investors about the ability to secure a Biologics License Application (BLA) for deramiocel from the FDA were exaggerated.

While promoting their drug, Capricor also reportedly concealed adverse information regarding the drug's safety and efficacy data from its Phase 2 HOPE-2 trial. Investors, getting caught up in these positive narratives, unknowingly bought securities at inflated prices based on misinformation.

When the truth about the data on deramiocel’s efficacy came to light, a significant drop in the stock price followed, leading to substantial losses for shareholders. The lawsuit asserts that the misleading statements led to the artificial inflation of Capricor's stock price, causing significant damage to investors once the truth was revealed.

Choosing the Right Counsel

Rosen Law Firm emphasizes the importance of selecting an experienced law firm to handle your case. Many firms that provide notices to potential class members lack proven litigation success and merely act as intermediaries. Rosen Law Firm has built a reputation in securing substantial settlements for investors, being ranked Number 1 by ISS Securities Class Action Services for the number of settlements achieved in 2017. In 2019 alone, they recovered over $438 million for investors. Their success record highlights their experience in this demanding field of securities law.

Founding partner Laurence Rosen has earned considerable recognition within the legal community, being named a 'Titan of the Plaintiffs' Bar' by Law360 in 2020. Numerous attorneys in their firm have also been acknowledged by Lawdragon and Super Lawyers for their achievements.

Final Notes

It is important to remember that no class has yet been certified, meaning investors are not formally represented unless they select legal counsel. Investors can choose to remain inactive or decide to join the class action as outlined above. For those considering action, your decision could play a pivotal role in recovering losses incurred during the tumultuous period of Capricor’s stock fluctuations.

Stay informed about updates regarding the class action by following Rosen Law Firm on LinkedIn and subscribe to their communications on other social platforms like Twitter and Facebook for the latest news.

In summary, the deadline for becoming a lead plaintiff is fast approaching. If you are an investor who faced significant losses with Capricor, consider taking action now for potential compensation in this securities fraud lawsuit.